FilingSEC EDGAR8-K
BlossomHill Therapeutics Announces Updated Data from Phase 1/2 SOLARA Trial of BH-30643
· SEC accepted
StagePhase 1/2
Filing content
The company reported a 45% objective response rate in patients with EGFR C797S-positive NSCLC. It plans to initiate a Phase 2 trial in Q1 2027.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…